NASDAQ:MNKD MannKind (MNKD) Stock Price, News & Analysis $5.03 -0.07 (-1.37%) Closing price 04:00 PM EasternExtended Trading$5.08 +0.05 (+1.09%) As of 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About MannKind Stock (NASDAQ:MNKD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MannKind alerts:Sign Up Key Stats Today's Range$5.00▼$5.1250-Day Range$4.92▼$6.1752-Week Range$3.97▼$7.63Volume1.30 million shsAverage Volume2.39 million shsMarket Capitalization$1.53 billionP/E Ratio71.86Dividend YieldN/APrice Target$9.21Consensus RatingBuy Company OverviewMannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Read More… Remove Ads MannKind Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreMNKD MarketRank™: MannKind scored higher than 45% of companies evaluated by MarketBeat, and ranked 603rd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingMannKind has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMannKind has only been the subject of 1 research reports in the past 90 days.Read more about MannKind's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth130.00% Earnings GrowthEarnings for MannKind are expected to grow by 130.00% in the coming year, from $0.10 to $0.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MannKind is 71.86, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.56.Price to Earnings Ratio vs. SectorThe P/E ratio of MannKind is 71.86, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.14.Read more about MannKind's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.67% of the float of MannKind has been sold short.Short Interest Ratio / Days to CoverMannKind has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in MannKind has recently decreased by 1.82%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMannKind does not currently pay a dividend.Dividend GrowthMannKind does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.67% of the float of MannKind has been sold short.Short Interest Ratio / Days to CoverMannKind has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in MannKind has recently decreased by 1.82%, indicating that investor sentiment is improving. News and Social Media1.6 / 5News Sentiment0.85 News SentimentMannKind has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for MannKind this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for MNKD on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added MannKind to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MannKind insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of MannKind is held by insiders.Percentage Held by Institutions49.55% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MannKind's insider trading history. Receive MNKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter. Email Address MNKD Stock News HeadlinesMannKind management to meet with Cantor FitzgeraldMarch 26 at 8:07 AM | markets.businessinsider.comMannKind (MNKD) Gets a Buy from Cantor FitzgeraldMarch 22, 2025 | markets.businessinsider.comNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, now!” Jim Rickards is one of the most connected men in Washington.March 28, 2025 | Paradigm Press (Ad)Brokerages Set MannKind Co. (NASDAQ:MNKD) Target Price at $9.21March 19, 2025 | americanbankingnews.comMannKind Corporation Showcases Positive Outcomes of Inhaled Insulin at ATTD 2025 with Anticipated sNDA Filing for Pediatric Use in 2025March 10, 2025 | quiverquant.comMannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22March 10, 2025 | globenewswire.comMannKind Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting NowMarch 1, 2025 | uk.finance.yahoo.comMannKind Corporation (NASDAQ:MNKD) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | msn.comSee More Headlines MNKD Stock Analysis - Frequently Asked Questions How have MNKD shares performed this year? MannKind's stock was trading at $6.43 at the beginning of 2025. Since then, MNKD stock has decreased by 21.8% and is now trading at $5.03. View the best growth stocks for 2025 here. How were MannKind's earnings last quarter? MannKind Co. (NASDAQ:MNKD) issued its quarterly earnings data on Wednesday, February, 26th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.03. The biopharmaceutical company had revenue of $76.78 million for the quarter, compared to analysts' expectations of $74.99 million. MannKind had a negative trailing twelve-month return on equity of 17.74% and a net margin of 8.07%. Who are MannKind's major shareholders? Top institutional shareholders of MannKind include Vanguard Group Inc. (5.82%), Nitorum Capital L.P. (3.17%), Geode Capital Management LLC (2.31%) and Arrowstreet Capital Limited Partnership (1.77%). Insiders that own company stock include Michael Castagna, Steven B Binder, Stuart A Tross, David Thomson and Alejandro Galindo. View institutional ownership trends. How do I buy shares of MannKind? Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MannKind own? Based on aggregate information from My MarketBeat watchlists, some other companies that MannKind investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Bausch Health Companies (BHC), Intel (INTC) and Netflix (NFLX). Company Calendar Last Earnings2/26/2025Today3/28/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MNKD CIK899460 Webwww.mannkindcorp.com Phone(818) 661-5000Fax661-775-2081Employees400Year Founded1991Price Target and Rating Average Stock Price Target$9.21 High Stock Price Target$12.00 Low Stock Price Target$6.50 Potential Upside/Downside+83.0%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$0.10 Trailing P/E Ratio71.93 Forward P/E Ratio50.35 P/E GrowthN/ANet Income$-11,940,000.00 Net Margins8.07% Pretax Margin9.37% Return on Equity-17.74% Return on Assets8.68% Debt Debt-to-Equity RatioN/A Current Ratio4.54 Quick Ratio4.17 Sales & Book Value Annual Sales$285.50 million Price / Sales5.35 Cash FlowN/A Price / Cash FlowN/A Book Value($0.91) per share Price / Book-5.53Miscellaneous Outstanding Shares303,591,000Free Float267,505,000Market Cap$1.53 billion OptionableOptionable Beta1.27 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free Report This page (NASDAQ:MNKD) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for May 7th. Because on that day, I believe we could see a $2 Trillion shock INTO the ma...Timothy Sykes | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.